THE ADDITION AT DAY 9 OF HD‐MTX TO THE (DA)‐EPOCH SCHEME WITH OR WITHOUT RITUXIMAB IS AN EFFECTIVE REGIMEN IN UNTREATED ADVANCED STAGE HIGH RISK LYMPHOMA: A FEASIBILITY STUDY

THE ADDITION AT DAY 9 OF HD‐MTX TO THE (DA)‐EPOCH SCHEME WITH OR WITHOUT RITUXIMAB IS AN EFFECTIVE REGIMEN IN UNTREATED ADVANCED STAGE HIGH RISK LYMPHOMA: A FEASIBILITY STUDY

Saved in:
Bibliographic Details
Published in:Hematological oncology Vol. 37; no. S2; pp. 441 - 442
Main Authors: Farina, G., Iaccarino, S., Troiano, M., Iovine, M., Vigliotti, M., Attingenti, E., Camera, A., Frigeri, F.
Format: Journal Article
Language:English
Published: Chichester Wiley Subscription Services, Inc 01-06-2019
Subjects:
Feasibility studies
Immunotherapy
Lymphoma
Monoclonal antibodies
Rituximab
Targeted cancer therapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:0278-0232
1099-1069
DOI:10.1002/hon.117_2631